

EU regulator to decide on one-shot J&J vaccine next week

2 March 2021



injection as opposed to two jabs, as well as being easier to store.

The Johnson & Johnson shot appears less protective than Pfizer and Moderna's regimes, which both have an efficacy of around 95 percent against all forms of COVID-19 from the classic [coronavirus](#) strain.

© 2021 AFP

Credit: Pixabay/CC0 Public Domain

The European Medicines Agency said on Tuesday that it is set to decide whether to authorise Johnson & Johnson's single-shot coronavirus vaccine for the EU on March 11.

If approved by the Amsterdam-based regulator, the [vaccine](#) would be the fourth to get the [green light](#) for the 27-nation bloc, in a boost for its slow-starting [vaccination programme](#).

"EMA's human medicines committee expected to give its recommendation for COVID-19 vaccine from Janssen on 11 March" at a special meeting, the watchdog said on Twitter.

Janssen-Cilag is the European subsidiary of US pharma giant J&J.

The EMA had previously said it expected to make a decision in mid-March, after Johnson & Johnson filed for approval on February 16.

The EU has so far approved three vaccines: Pfizer-BioNTech, Moderna and AstraZeneca-Oxford.

But the J&J would be the first that requires a single

APA citation: EU regulator to decide on one-shot J&J vaccine next week (2021, March 2) retrieved 28 May 2021 from <https://medicalxpress.com/news/2021-03-eu-one-shot-jj-vaccine-week.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.